Asunercept (APG101)
Clinical Efficacy in Two Indications
Our lead immuno-oncology candidate asunercept (APG101) is in clinical development for the treatment of a variety of solid tumors and malignant hematological diseases. It has demonstrated statistically significant efficacy in a controlled phase II proof-of-concept trial in recurrent glioblastoma. Patients with a certain biomarker experienced the greatest benefit from treatment with asunercept. Apogenix is developing a companion diagnostic test based on this biomarker, so asunercept can be used as a personalized therapy.
Technology
The Apogenix team has created the HERA technology platform for the development of novel hexavalent receptor agonists that target different TNFSF-dependent signaling pathways, which play a crucial role in the regulation of the immune response. These fusion proteins offer clear advantages over other biologics such as antibodies and have the potential for broad application in oncology.
News
May 23, 2018
Apogenix Provides Update on Clinical Development of Asunercept
October 5, 2017
Apogenix Granted Orphan Designation by the European Commission for Asunercept to Treat Myelodysplastic Syndromes